Utilization patterns, cost analysis, and monitoring burden of warfarin and rivaroxaban in Oman: a retrospective study (2019–2024)
Authors:
- Hanin Salim Al WashahiHWHanin Salim Al Washahi
- Abdullah Salim Haji Al-KaabiAAAbdullah Salim Haji Al-Kaabi
- Yaman W. KassabYKYaman W. Kassab
- Ahmed Alaa Al-TemimiAAAhmed Alaa Al-Temimi
- 15 October 2025
- journal article
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 75-77
Abstract
Background: Warfarin and Rivaroxaban are common anticoagulants with distinct profiles. Warfarin, a vitamin K an¬tagonist, requires frequent international normalized ratio (INR) monitoring and dose adjustments. Rivaroxaban, a di¬rect oral anticoagulant (DOAC), allows fixed dosing with minimal monitoring but is more expensive. Aim: To compare prescribing trends, patient demographics, and cost implications of warfarin and rivaroxaban in Oman from January 2019 to May 2024. Methodology: Prescription data were reviewed for drug utilization, number of patients, prescrip¬tions, tablets dispensed, and related costs. INR test counts for warfarin were also analyzed. Costs were reported in Omani Rial (R.O). Results: Warfarin was prescribed to 238 patients, totaling 6,813 prescriptions and 292,812 tablets. Rivaroxaban was prescribed to 28 patients, with 445 prescriptions and 11,491 tablets. Total cost: warfarin (12,143.28 R.O), rivaroxaban (7,554.38 R.O). Switching all warfarin users to rivaroxaban would cost 30,184.56 R.O. INR moni¬toring for warfarin users involved 1,626 tests. Conclusion: Warfarin remains widely used in Oman due to lower cost, despite rivaroxaban’s ease of use. High expense limits rivaroxaban adoption. Future studies should explore long-term outcomes and cost-effectiveness of broader DOAC use.Keywords
This publication has 8 references indexed in Scilit:
- Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysisBMJ, 2019
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- National Trends in Ambulatory Oral Anticoagulant UseThe American Journal of Medicine, 2015
- Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registryBritish Journal of Clinical Pharmacology, 2014
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Evidence-Based Management of Anticoagulant TherapyChest, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010